165 related articles for article (PubMed ID: 28450046)
1. Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications.
Hidalgo A; Cruz A; Pérez-Gil J
Biochim Biophys Acta Biomembr; 2017 Sep; 1859(9 Pt B):1740-1748. PubMed ID: 28450046
[TBL] [Abstract][Full Text] [Related]
2. Barrier or carrier? Pulmonary surfactant and drug delivery.
Hidalgo A; Cruz A; Pérez-Gil J
Eur J Pharm Biopharm; 2015 Sep; 95(Pt A):117-27. PubMed ID: 25709061
[TBL] [Abstract][Full Text] [Related]
3. The Lord of the Lungs: The essential role of pulmonary surfactant upon inhalation of nanoparticles.
Garcia-Mouton C; Hidalgo A; Cruz A; Pérez-Gil J
Eur J Pharm Biopharm; 2019 Nov; 144():230-243. PubMed ID: 31560956
[TBL] [Abstract][Full Text] [Related]
4. Restoring pulmonary surfactant membranes and films at the respiratory surface.
Echaide M; Autilio C; Arroyo R; Perez-Gil J
Biochim Biophys Acta Biomembr; 2017 Sep; 1859(9 Pt B):1725-1739. PubMed ID: 28341439
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins.
Guagliardo R; Pérez-Gil J; De Smedt S; Raemdonck K
J Control Release; 2018 Dec; 291():116-126. PubMed ID: 30321577
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical properties of nanoparticles affecting their fate and the physiological function of pulmonary surfactants.
Liu Q; Guan J; Song R; Zhang X; Mao S
Acta Biomater; 2022 Mar; 140():76-87. PubMed ID: 34843949
[TBL] [Abstract][Full Text] [Related]
7. Structure-function relationships in pulmonary surfactant membranes: from biophysics to therapy.
Lopez-Rodriguez E; Pérez-Gil J
Biochim Biophys Acta; 2014 Jun; 1838(6):1568-85. PubMed ID: 24525076
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein corona.
Hu G; Jiao B; Shi X; Valle RP; Fan Q; Zuo YY
ACS Nano; 2013 Dec; 7(12):10525-33. PubMed ID: 24266809
[TBL] [Abstract][Full Text] [Related]
9. Computer simulations of lung surfactant.
Baoukina S; Tieleman DP
Biochim Biophys Acta; 2016 Oct; 1858(10):2431-2440. PubMed ID: 26922885
[TBL] [Abstract][Full Text] [Related]
10. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
Yu HP; Aljuffali IA; Fang JY
Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
[TBL] [Abstract][Full Text] [Related]
11. Can nanotechnology hit the spot in aerosol-based drug delivery for lung disorders?
Joshi N
Ther Deliv; 2018 Mar; 9(4):233-236. PubMed ID: 29495926
[No Abstract] [Full Text] [Related]
12. High-resolution investigation of nanoparticle interaction with a model pulmonary surfactant monolayer.
Sachan AK; Harishchandra RK; Bantz C; Maskos M; Reichelt R; Galla HJ
ACS Nano; 2012 Feb; 6(2):1677-87. PubMed ID: 22288983
[TBL] [Abstract][Full Text] [Related]
13. The influence of pulmonary surfactant on nanoparticulate drug delivery systems.
Schleh C; Rothen-Rutishauser B; Kreyling WG
Eur J Pharm Biopharm; 2011 Apr; 77(3):350-2. PubMed ID: 21195761
[TBL] [Abstract][Full Text] [Related]
14. Protein-lipid interactions and surface activity in the pulmonary surfactant system.
Serrano AG; Pérez-Gil J
Chem Phys Lipids; 2006 Jun; 141(1-2):105-18. PubMed ID: 16600200
[TBL] [Abstract][Full Text] [Related]
15. The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels.
De Backer L; Braeckmans K; Demeester J; De Smedt SC; Raemdonck K
Nanomedicine (Lond); 2013 Oct; 8(10):1625-38. PubMed ID: 23418856
[TBL] [Abstract][Full Text] [Related]
16. Are Plant-Based Carbohydrate Nanoparticles Safe for Inhalation? Investigating Their Interactions with the Pulmonary Surfactant Using Langmuir Monolayers.
Gravel-Tatta L; DeWolf C; Badia A
Langmuir; 2021 Oct; 37(42):12365-12376. PubMed ID: 34644076
[TBL] [Abstract][Full Text] [Related]
17. Computational Investigations of the Interaction between the Cell Membrane and Nanoparticles Coated with a Pulmonary Surfactant.
Bai X; Xu M; Liu S; Hu G
ACS Appl Mater Interfaces; 2018 Jun; 10(24):20368-20376. PubMed ID: 29808987
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine for respiratory diseases.
Pison U; Welte T; Giersig M; Groneberg DA
Eur J Pharmacol; 2006 Mar; 533(1-3):341-50. PubMed ID: 16434033
[TBL] [Abstract][Full Text] [Related]
19. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.
Jin Z; Gao Q; Wu K; Ouyang J; Guo W; Liang XJ
Adv Drug Deliv Rev; 2023 Nov; 202():115111. PubMed ID: 37820982
[TBL] [Abstract][Full Text] [Related]
20. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles.
Beck-Broichsitter M; Ruppert C; Schmehl T; Günther A; Seeger W
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):474-81. PubMed ID: 24184425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
